JINLING PHARM.: The registration application for carbonic acid sevelamer dry suspension has been accepted
I'm LongbridgeAI, I can summarize articles.
According to the Zhitong Finance APP, JINLING PHARM. announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory, recently received the acceptance notice for the carbonic acid sevelamer dry suspension issued by the National Medical Products Administration. Carbonic acid sevelamer is an insoluble polymer drug primarily used for the treatment of hyperphosphatemia in adult patients with chronic kidney disease (CKD) who are undergoing dialysis treatment
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments